ALLO stock forecast, quote, news & analysis
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases... Show more
Why Allogene Therapeutics (ALLO) Stock Is Down -25% in the Last 30 Days
Key Takeaways
- Allogene Therapeutics shares have declined roughly 25% over the trailing 30 days, sliding from about $1.65 to $1.23 per share.
- The sell-off was driven primarily by broad risk-off sentiment in small-cap biotechnology and profit-taking after a strong first-half 2026 run, rather than a single company-specific negative catalyst.
- Over the last quarter, the stock is down approximately 30%, unwinding from a mid-August peak near $2.23.
- Allogene remains a clinical-stage developer of "off-the-shelf" allogeneic CAR T cell therapies, with lead asset cema-cel advancing in the pivotal Phase 2 ALPHA3 trial.
- Near-term catalysts include fourth-quarter 2026 data for ALLO-329 in autoimmune disease and the company's next quarterly earnings report.
- Allogene reported $423.6 million in cash, cash equivalents, and investments as of June 30, 2026, with a runway expected into 2029.
- For deeper insight into Allogene's valuation and outlook, explore its Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to discover AI-driven trading strategies across thousands of tickers.
Allogene Therapeutics (ALLO) Company Overview and Market Position
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing "off-the-shelf" allogeneic CAR T cell therapies. Unlike autologous CAR T treatments, which are engineered from a patient's own cells, Allogene's candidates are manufactured from healthy donor cells, giving them the potential to be more scalable, faster to administer, and more broadly accessible.
The company's lead program is cema-cel (cemacabtagene ansegedleucel), which is being evaluated in the pivotal Phase 2 ALPHA3 trial as a first-line, MRD-guided consolidation therapy for newly diagnosed large B-cell lymphoma. Allogene is also advancing ALLO-329 in the Phase 1 RESOLUTION basket study across autoimmune indications such as systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis, as well as ALLO-316 for CD70-positive renal cell carcinoma. With no marketed product, revenue is limited to collaboration income, and investors follow the stock primarily for its clinical catalysts, pipeline breadth, and cash position.
Allogene Therapeutics (ALLO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALLO shares have fallen roughly 25%, declining from a closing price near $1.65 to approximately $1.23. The move extended a longer downward trend: over the trailing quarter, the stock is down about 30%, from a close near $1.75 three months ago. After peaking near $2.23 in mid-August, the shares posted a series of lower closes through September and October, indicating persistent selling pressure rather than a single sharp one-day drop.
What Drove ALLO Stock Price in the Last 30 Days
The recent decline unfolded without one clearly identifiable company-specific negative event. Trading commentary during the period repeatedly attributed the weakness to broader market softness and risk-off sentiment across speculative small-cap biotechnology, with ALLO logging multiple consecutive sessions of lower closes. The pullback also followed a substantial year-to-date advance, suggesting profit-taking by investors who had ridden the stock higher earlier in the year.
Investor positioning added to the pressure. A regulatory filing disclosed that an executive sold roughly 36,300 shares in late October, a development that can weigh on sentiment for a thinly covered, clinical-stage name. Additionally, the stock traded lower as investors positioned ahead of two closely watched catalysts: fourth-quarter 2026 data for ALLO-329 and the company's next earnings report, both of which carry binary, event-driven risk for a company without recurring product revenue.
What Drove ALLO Stock Performance Over the Last Quarter
The quarterly decline reflects a broader unwind of the optimism that lifted Allogene earlier in 2026. The stock gained more than 50% year to date at one point, driven by favorable ALPHA3 interim data showing 58.3% MRD negativity in treated patients versus 16.7% with observation, faster-than-expected trial site activation, and a successful April public offering that extended the company's cash runway. As the market repriced risk in speculative biotech, those gains partially reversed, and the shares drifted lower despite a narrower-than-expected second-quarter loss and disciplined operating-expense guidance of about $225 million for 2026. The overall trend highlights how a pre-revenue, catalyst-dependent biotech can be highly sensitive to shifts in risk appetite even in the absence of negative trial news.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing and most relevant AI trading bots. While Tickeron offers hundreds of AI-driven bots that trade thousands of tickers, only those demonstrating standout performance and relevance appear in this featured section. The bots vary widely in strategy, trading timeframe, and performance metrics, allowing users to compare approaches suited to different market conditions and risk preferences. For traders seeking a data-driven, systematic perspective on names like Allogene Therapeutics, the page provides a useful starting point for evaluating automated strategies. Visit the section to explore how these tools are tracking current market dynamics.
ALLO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape Allogene's stock. The most immediate is the fourth-quarter 2026 clinical and translational data update from the RESOLUTION study of ALLO-329 in autoimmune disease, which management has indicated will include safety, efficacy, and translational findings across multiple dose cohorts. The company's next quarterly earnings report also carries weight, as investors assess operating expenses, cash burn, and enrollment progress.
Further out, the pivotal ALPHA3 trial remains the central value driver, with an interim analysis of the primary event-free survival endpoint expected in mid-2027. Competitive dynamics in both allogeneic CAR T oncology and the emerging autoimmune cell-therapy space, along with broader macroeconomic conditions affecting risk appetite, will also matter. As with any pre-revenue biotech, execution risk, financing considerations, and regulatory developments should be monitored closely. This information is provided for context and does not constitute a recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALLO's Stochastic Oscillator sits in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALLO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.824) is normal, around the industry mean (3.498). P/E Ratio (-1.576) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Nikkei 225?
Navigating the Cryptocurrency Exchanges: A Comprehensive Guide
What is the Direxion Daily Gold Miners Index Bull 2X (NUGT) ETF and How Does It Work?
AI Trading Bots: Top 6 Auto-Trader, Our Brokerage, on January 24, 2025
Which order should I use, a Stop-Loss or a Stop-Limit Order?
General Information
a developer of allogeneic chimeric antigen receptor therapy
Industry Biotechnology